%0 Journal Article
%T Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia.
%A Shah S
%A Kline EG
%A Haidar G
%A Squires KM
%A Pogue JM
%A McCreary EK
%A Ludwig J
%A Clarke LG
%A Stellfox M
%A Van Tyne D
%A Shields RK
%J Clin Infect Dis
%V 0
%N 0
%D 2024 Jun 21
%M 38902935
%F 20.999
%R 10.1093/cid/ciae332
%X Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia we found those treated with ceftazidime-avibactam were more likely to develop resistance (defined as ≥4-fold increased MIC) than those treated with ceftolozane-tazobactam (40% vs. 10%; P=0.002). Ceftazidime-avibactam resistance was associated with new mutations in ampC and efflux regulatory pathways.